Breakthrough Cancer Therapy: This Medical Company Announces Phase 1b Safety Evaluation Completion

Processa Pharmaceuticals Advances on Phase 1b Safety Evaluation of NGC-Cap in Advanced Cancer Patients, Phase 2 Doses Recommended.

This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

In recently reported news, Processa Pharmaceuticals (OTC: PCSA) announced the successful completion of the Phase 1b safety evaluation of its breakthrough therapy, NGC-Cap, in patients with advanced cancer. This developmen…